A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...
Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...
An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...
Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...
MarketBeat on MSN2d
Eli Lilly: 4 Reasons Investors Shouldn't Miss This OpportunityEli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks ...
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback